Press Detail





Biotest AG: Pentaglobin(R) shows high binding capacity against the current EHEC strain and its Shiga-like toxin 2

Biotest AG / Key word(s): Miscellaneous

22.06.2011 / 16:07

Pentaglobin(R) shows high binding capacity against the current EHEC strain
and its Shiga-like toxin 2

- First analysis show positive results
- Pentaglobin(R) contains antibodies with high binding capacity against
  surface antigens of the current EHEC strain HUSEC041

Dreieich, 22. June 2011. New preclinical data might give new hopes for EHEC
patients and their physicians. The human polyvalent IgM preparation
Pentaglobin(R)  contains antibodies with high binding capacity against
surface antigens of the current EHEC strain HUSEC041 (O104:H4). Assays
carried out last week by the Institute for Hygiene, University Münster,
revealed homogenous antibody titers in a range of up to 1:800 against
surface antigens of the current strain HUSEC041 in different Pentaglobin(R)
batches. This activity was related to all three immunoglobulin classes of
Pentaglobin(R): IgG, IgM, IgA.

Furthermore, immunoblot assays demonstrated binding of Pentaglobin(R) to
Shiga-like toxin 2 which is produced by HUSEC041 causing the hemolytic
uremic syndrome (HUS) in severely infected EHEC patients.

Due to the limited experience in few patients no final conclusion on the
clinical efficacy of Pentaglobin(R) in EHEC patients is currently possible.
Nevertheless, this data imply that Pentaglobin(R) might be a possible
treatment option for patients with EHEC infection.
 
About Pentaglobin(R):
Pentaglobin(R) is the first and only IgM-enriched immunoglobulin
preparation for intravenous use. Pentaglobin(R) significantly increases the
survival rate of patients with severe bacterial infections and acts against
a broad spectrum of bacterial pathogens. Pentaglobin(R), especially when
administered in an early state of disease, exhibits an anti-bacterial mode
of action by its fast neutralization of bacterial endo- and exotoxins and
shows an anti-inflammatory mode of action by scavenging excessively
activated complement factors. Pentaglobin(R) is licensed in several
countries, mainly for the treatment of bacterial infections in combination
with antibiotics. The recommended dosage for a patient with 70 kg is 350 ml
per day on three consecutive days.
 
Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest

Biotest is a provider of plasmatic and biotherapeutic drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of
application of clinical immunology, haematology and intensive medicine. In
its Plasma Protein segment, Biotest develops and markets immunoglobulins,
coagulation factors and albumins based on human blood plasma. These are
used for diseases of the immune and haematopoietic systems. In the
Biotherapeutic segment, Biotest researches into the clinical development of
monoclonal antibodies, including in the indications of rheumatoid arthritis
and cancer of plasma cells. Biotest has more than 1.600 employees
worldwide. The preference shares of Biotest AG are listed in the SDAX on
the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406, 
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart


End of Corporate News

---------------------------------------------------------------------

22.06.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                                
Company:     Biotest AG                                             
             Landsteinerstraße 5                                    
             63303 Dreieich                                         
             Deutschland                                            
Phone:       0 61 03 - 8 01-0                                       
Fax:         0 61 03 - 8 01-150                                     
E-mail:      investor_relations@biotest.de                          
Internet:    http://www.biotest.de                                  
ISIN:        DE0005227235, DE0005227201                             
WKN:         522723, 522720                                         
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
129483 22.06.2011